Skip to main content

Advertisement

SpringerLink
Log in

Circulating tumor cells in solid cancer: Tumor marker of clinical relevance?

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Circulating tumor cells (CTC) can be detected in the peripheral blood of patients with a variety of solid cancers. Because of their very low frequency, these tumor cells are not easily detected using conventional cytology methods. In the past decade, numerous groups have attempted to detect CTC of solid malignancies using the highly sensitive reverse transcriptase polymerase chain reaction, which has been shown to be superior to conventional techniques. However, the biological significance of CTC and the therapeutic relevance of their detection are still debated. This article reviews the most recent findings on this subject, and discusses the potential of identification and molecular characterization of the subset of CTC responsible for metastasis development. Confirming the prognostic value of CTC would provide clinicians with a unique tool for better stratification of patients’ risk and provide basic researchers with a new target for the development of novel therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448–456.

    Article  PubMed  CAS  Google Scholar 

  2. Chang YS, di Tomaso E, McDonald DM, et al.: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000, 97:14608–14613.

    Article  PubMed  CAS  Google Scholar 

  3. Meng S, Tripathy D, Frenkel EP, et al.: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004, 10:8152–8162.

    Article  PubMed  Google Scholar 

  4. Mehes G, Witt A, Kubista E, Ambros PF: Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001, 159:17–20.

    PubMed  CAS  Google Scholar 

  5. Luzzi KJ, MacDonald IC, Schmidt EE, et al.: Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases, Am J Pathol 1998, 153:865–873.

    PubMed  CAS  Google Scholar 

  6. Fidler IJ: The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer 2003, 3:453–458.

    Article  PubMed  CAS  Google Scholar 

  7. Hunter KW: Host genetics and tumour metastasis. Br J Cancer 2004, 90:752–755.

    Article  PubMed  CAS  Google Scholar 

  8. Wittekind C, Neid M: Cancer invasion and metastasis. Oncology 2005, 69(Suppl 1):14–16.

    Article  PubMed  Google Scholar 

  9. Dolken G: Detection of minimal residual disease. Adv Cancer Res 2001, 82:133–185.

    Article  PubMed  CAS  Google Scholar 

  10. Jung R, Petersen K, Kruger W, et al.: Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999, 81:870–873.

    Article  PubMed  CAS  Google Scholar 

  11. Mocellin S, Rossi C, Pilati P, et al.: Quantitative real time PCR: a powerful ally in cancer research. Trends Mol Med 2003, 9:189–195.

    Article  PubMed  CAS  Google Scholar 

  12. Weigelt B, Bosma AJ, Hart AA, et al.: Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003, 88:1091–1094.

    Article  PubMed  CAS  Google Scholar 

  13. Smith BM, Slade MJ, English J, et al.: Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000, 18:1432–1439.

    PubMed  CAS  Google Scholar 

  14. Lauschke H, Caspari R, Friedl W, et al.: Detection of APC and k-ras mutations in the serum of patients with colorectal cancer. Cancer Detect Prev 2001, 25:55–61.

    PubMed  CAS  Google Scholar 

  15. Ashida S, Okuda H, Chikazawa M, et al.: Detection of circulating cancer cells with Von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 2000, 6:3817–3822.

    PubMed  CAS  Google Scholar 

  16. Schleiermacher G, Peter M, Oberlin O, et al.: Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003, 21:85–91.

    Article  PubMed  Google Scholar 

  17. Silva JM, Rodriguez R, Garcia JM, et al.: Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002, 50:530–534.

    Article  PubMed  CAS  Google Scholar 

  18. Witzig TE, Bossy B, Kimlinger T, et al.: Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002, 8:1085–1091.

    PubMed  Google Scholar 

  19. Allard WJ, Matera J, Miller MC, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897–6904.

    Article  PubMed  Google Scholar 

  20. Tsao H, Nadiminti U, Sober AJ, Bigby M: A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001, 137:325–330.

    PubMed  CAS  Google Scholar 

  21. Smith B, Selby P, Southgate J, et al.: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227–1229.

    Article  PubMed  CAS  Google Scholar 

  22. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al.: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683–689.

    Article  PubMed  CAS  Google Scholar 

  23. Osella-Abate S, Savoia P, Quaglino P, et al.: Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003, 89:1457–1462.

    Article  PubMed  CAS  Google Scholar 

  24. Hoon DS, Bostick P, Kuo C, et al.: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000, 60:2253–2257.

    PubMed  CAS  Google Scholar 

  25. Curry BJ, Myers K, Hersey P: MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999, 17:2562–2571.

    PubMed  CAS  Google Scholar 

  26. Ghossein RA, Coit D, Brennan M, et al.: Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998, 4:419–428.

    PubMed  CAS  Google Scholar 

  27. Proebstle TM, Jiang W, Hogel J, et al.: Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 2000, 82:118–123.

    Article  PubMed  CAS  Google Scholar 

  28. Schmidt H, Sorensen BS, Fode K, et al.: Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 2005, 15:409–416.

    Article  PubMed  CAS  Google Scholar 

  29. Palmieri G, Ascierto PA, Perrone F, et al.: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003, 21:767–773.

    Article  PubMed  CAS  Google Scholar 

  30. Gogas H, Kefala G, Bafaloukos D, et al.: Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002, 87:181–186.

    Article  PubMed  CAS  Google Scholar 

  31. Domingo-Domenech J, Molina R, Castel T, et al.: Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon—comparison with tyrosinase rt-PCR. Oncology 2005, 68:341–349.

    Article  PubMed  CAS  Google Scholar 

  32. Reynolds SR, Albrecht J, Shapiro RL, et al.: Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:1497–1502.

    PubMed  CAS  Google Scholar 

  33. Kufer P, Zippelius A, Lutterbuse R, et al.: Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002, 62:251–261.

    PubMed  CAS  Google Scholar 

  34. Medic S, Pearace RL, Heenan PJ et al.: Molecular markers of circulating melanoma cells. Pigment Cell Res 2007, 20:80–91.

    Article  PubMed  CAS  Google Scholar 

  35. Mocellin S, Del Fiore P, Guarnieri L, et al.: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004, 111:741–745.

    Article  PubMed  CAS  Google Scholar 

  36. Brownbridge GG, Gold J, Edward M, MacKie RM: Evaluation of the use of tyrosinase-specific and melanA/ MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001, 144:279–287.

    Article  PubMed  CAS  Google Scholar 

  37. Voit C, Kron M, Rademaker J, et al.: Molecular staging in stage II and III melanoma patients and its effect on longterm survival. J Clin Oncol 2005, 23:1218–1227.

    Article  PubMed  CAS  Google Scholar 

  38. Wascher RA, Morton DL, Kuo C, et al.: Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003, 21:2558–2563.

    Article  PubMed  CAS  Google Scholar 

  39. Visus C, Andres R, Mayordomo JI, et al.: Prognostic role of circulating melanoma cells detected by reverse transcriptasepolymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res 2007, 17:83–89.

    Article  PubMed  CAS  Google Scholar 

  40. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781–791.

    Article  PubMed  CAS  Google Scholar 

  41. Budd GT, Cristofanilli M, Ellis MJ, et al.: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403–6409.

    Article  PubMed  CAS  Google Scholar 

  42. Ulmer A, Schmidt-Kittler O, Fischer J, et al.: Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 2004, 10:531–537.

    Article  PubMed  CAS  Google Scholar 

  43. Moreno JG, Miller MC, Gross S, et al.: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005, 65:713–718.

    Article  PubMed  Google Scholar 

  44. Shimazui T, Yoshikawa K, Uemura H, et al.: The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 2004, 101:963–968.

    Article  PubMed  CAS  Google Scholar 

  45. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al.: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002, 20:3404–3412.

    Article  PubMed  CAS  Google Scholar 

  46. Jotsuka T, Okumura Y, Nakano S, et al.: Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 2004, 135:419–426.

    Article  PubMed  Google Scholar 

  47. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al.: Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004, 108:620–627.

    Article  PubMed  CAS  Google Scholar 

  48. Pierga JY, Bonneton C, Vincent-Salomon A, et al.: Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004, 10:1392–1400.

    Article  PubMed  CAS  Google Scholar 

  49. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006, 13:1033–1067.

    Article  PubMed  CAS  Google Scholar 

  50. Zieglschmid V, Hollmann C, Gutierrez B, et al.: Heterogeneous expression of tumor-associated genes in disseminated breast cancer cells. Anticancer Res 2007, 27:1769–1776.

    PubMed  CAS  Google Scholar 

  51. Bozionellou V, Mavroudis D, Perraki M, et al.: Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004, 10:8185–8194.

    Article  PubMed  CAS  Google Scholar 

  52. Halabi S, Small EJ, Hayes DF, et al.: Prognostic significance of reverse transcriptase polymerase chain reaction for prostatespecific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003, 21:490–495.

    Article  PubMed  CAS  Google Scholar 

  53. Thomas J, Gupta M, Grasso Y, et al.: Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002, 20:3213–3218.

    Article  PubMed  CAS  Google Scholar 

  54. Morgan TM, Lange PH, Vessella RL et al.: Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007, 12:3000–3009.

    Article  PubMed  CAS  Google Scholar 

  55. Shariat SF, Kattan MW, Song W, et al.: Early postoperative peripheral blood reverse transcription PCR assay for prostatespecific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res 2003, 63:5874–5878.

    PubMed  CAS  Google Scholar 

  56. de la Taille A, Olsson CA, Buttyan R, et al.: Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 1999, 84:360–364.

    Article  PubMed  Google Scholar 

  57. Okegawa T, Noda H, Kato M, et al.: Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 2000, 44:210–218.

    Article  PubMed  CAS  Google Scholar 

  58. Khair G, Monson JR, Greenman J: Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. Dis Colon Rectum 2007, 50:1188–1203.

    Article  PubMed  Google Scholar 

  59. Koch M, Kienle P, Hinz U, et al.: Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005, 241:199–205.

    Article  PubMed  Google Scholar 

  60. Bessa X, Pinol V, Castellvi-Bel S, et al.: Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg 2003, 237:368–375.

    Article  PubMed  Google Scholar 

  61. Yamaguchi K, Takagi Y, Aoki S, et al.: Significant detection of circulating cancer cells in the blood by reverse transcriptasepolymerase chain reaction during colorectal cancer resection. Ann Surg 2000, 232:58–65.

    Article  PubMed  CAS  Google Scholar 

  62. Schuster R, Max N, Mann B, et al.: Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004, 108:219–227.

    Article  PubMed  CAS  Google Scholar 

  63. Ring AE, Zabaglo L, Ormerod MG, et al.: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005, 92:906–912.

    Article  PubMed  CAS  Google Scholar 

  64. Smirnov DA, Zweitzig DR, Foulk BW, et al.: Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65:4993–4997.

    Article  PubMed  CAS  Google Scholar 

  65. Schardt JA, Meyer M, Hartmann CH, et al.: Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005, 8:227–239.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncological and Surgical Sciences, University of Padova, via Giustiniani 2, 35128, Padova, Italy

    Simone Mocellin

Authors
  1. Loris Bertazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Mocellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donato Nitti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Mocellin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertazza, L., Mocellin, S. & Nitti, D. Circulating tumor cells in solid cancer: Tumor marker of clinical relevance?. Curr Oncol Rep 10, 137–146 (2008). https://doi.org/10.1007/s11912-008-0022-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0022-y

Keywords

Search

Navigation